Biodesix, Inc. (NASDAQ:BDSX) Given Average Rating of “Buy” by Brokerages

Shares of Biodesix, Inc. (NASDAQ:BDSX) have been given a consensus recommendation of “Buy” by the six analysts that are currently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $3.06.

BDSX has been the topic of a number of research analyst reports. Scotiabank assumed coverage on shares of Biodesix in a report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 price objective on the stock. Craig Hallum assumed coverage on Biodesix in a research note on Friday, July 26th. They issued a “buy” rating and a $3.00 price target on the stock.

Biodesix Price Performance

BDSX opened at $1.37 on Friday. The stock has a market cap of $199.29 million, a P/E ratio of -3.51 and a beta of 1.22. Biodesix has a 12 month low of $1.15 and a 12 month high of $2.21. The company has a quick ratio of 3.28, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. The company has a fifty day simple moving average of $1.67 and a 200 day simple moving average of $1.61.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings results on Friday, November 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. The company had revenue of $18.15 million during the quarter, compared to the consensus estimate of $18.45 million. During the same period in the prior year, the company earned ($0.12) earnings per share. On average, research analysts expect that Biodesix will post -0.35 EPS for the current year.

Insider Buying and Selling at Biodesix

In related news, Chairman John Patience acquired 75,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was bought at an average price of $1.38 per share, for a total transaction of $103,500.00. Following the acquisition, the chairman now directly owns 2,153,298 shares of the company’s stock, valued at approximately $2,971,551.24. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Chairman John Patience bought 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was acquired at an average cost of $1.38 per share, with a total value of $103,500.00. Following the completion of the purchase, the chairman now owns 2,153,298 shares of the company’s stock, valued at $2,971,551.24. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Matthew Strobeck bought 40,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were purchased at an average price of $1.40 per share, for a total transaction of $56,000.00. Following the completion of the acquisition, the director now owns 2,606,879 shares of the company’s stock, valued at $3,649,630.60. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have sold 1,379 shares of company stock worth $2,165. Insiders own 69.20% of the company’s stock.

Institutional Investors Weigh In On Biodesix

A number of institutional investors and hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC acquired a new position in Biodesix during the second quarter worth approximately $3,326,000. Farallon Capital Management LLC acquired a new position in shares of Biodesix during the 2nd quarter worth approximately $2,874,000. CVI Holdings LLC acquired a new stake in Biodesix during the 2nd quarter valued at $59,000. Essex Investment Management Co. LLC boosted its position in Biodesix by 1.4% during the first quarter. Essex Investment Management Co. LLC now owns 925,614 shares of the company’s stock worth $1,324,000 after purchasing an additional 12,669 shares during the period. Finally, AIGH Capital Management LLC increased its holdings in shares of Biodesix by 74.0% in the second quarter. AIGH Capital Management LLC now owns 5,779,812 shares of the company’s stock valued at $8,843,000 after purchasing an additional 2,458,727 shares during the last quarter. 20.96% of the stock is owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.